154 related articles for article (PubMed ID: 33980938)
1. Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study.
Yamaguchi A; Honda M; Ishiguro H; Kataoka M; Kataoka TR; Shimizu H; Torii M; Mori Y; Kawaguchi-Sakita N; Ueno K; Kawashima M; Takada M; Suzuki E; Nakamoto Y; Kawaguchi K; Toi M
Sci Rep; 2021 May; 11(1):10112. PubMed ID: 33980938
[TBL] [Abstract][Full Text] [Related]
2. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden DI; Lipson JA; Telli ML; Ford JM; Rubin DL
J Am Med Inform Assoc; 2013; 20(6):1059-66. PubMed ID: 23785100
[TBL] [Abstract][Full Text] [Related]
4. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
[TBL] [Abstract][Full Text] [Related]
5. Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
Kamiya S; Satake H; Hayashi Y; Ishigaki S; Ito R; Kawamura M; Taoka T; Iwano S; Naganawa S
Breast Cancer; 2022 Jan; 29(1):164-173. PubMed ID: 34529241
[TBL] [Abstract][Full Text] [Related]
6. Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI.
Xu WJ; Zheng BJ; Lu J; Liu SY; Li HL
BMC Med Imaging; 2023 Jun; 23(1):70. PubMed ID: 37264313
[TBL] [Abstract][Full Text] [Related]
7. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
[TBL] [Abstract][Full Text] [Related]
8. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
9. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
10. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
11. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
[TBL] [Abstract][Full Text] [Related]
12. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
[TBL] [Abstract][Full Text] [Related]
13. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
16. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
17. DCE-MRI Performance in Triple Negative Breast Cancers: Comparison with Non-Triple Negative Breast Cancers.
Chen H; Min Y; Xiang K; Chen J; Yin G
Curr Med Imaging; 2022; 18(9):970-976. PubMed ID: 35232365
[TBL] [Abstract][Full Text] [Related]
18. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy.
Yoshikawa K; Ishida M; Kan N; Yanai H; Tsuta K; Sekimoto M; Sugie T
World J Surg Oncol; 2020 Jul; 18(1):177. PubMed ID: 32693794
[TBL] [Abstract][Full Text] [Related]
20. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging.
Kim JJ; Kim JY; Suh HB; Hwangbo L; Lee NK; Kim S; Lee JW; Choo KS; Nam KJ; Kang T; Park H
Eur Radiol; 2022 Feb; 32(2):822-833. PubMed ID: 34345946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
